Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of
subjects with central (gonadotropin-dependent) precocious puberty, when administered as two
injections six months apart.